Healthy Brain Clinic

Running trials

• Recruiting

  A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

  NCT07717411· Phase 3· Source

• Recruiting

  A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  NCT07794579· Phase 3· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

  NCT07775300· Phase 3· Source

• Recruiting

  A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

  NCT07602582· Phase 3· Source

• Recruiting

  A Study of LY3439539 in Participants With Alzheimer's Disease

  NCT07598370· Phase 1· Source

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

  NCT06976216· Phase 3· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Source

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Source

• Active, not recruiting

  A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

  NCT05738486· Phase 3· Source

• Active, not recruiting

  A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

  NCT05026866· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease5 recruiting
• Depression1 recruiting
• Obesity1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

  NCT06901349· Phase 2· Source

• Terminated

  Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT05026177· Phase 3· Source